Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Win-Max is a veterinary pharmaceutical product, specifically a combination injectable solution used in livestock and companion animals. It typically contains a combination of an antibiotic (often oxytetracycline) and a non-steroidal anti-inflammatory drug (NSAID, such as flunixin meglumine). This combination is designed to provide simultaneous antimicrobial activity against susceptible pathogens and anti-inflammatory, analgesic, and anti-pyretic effects to manage pain and fever associated with respiratory infections or other inflammatory conditions. The antibiotic component inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, while the NSAID component inhibits cyclooxygenase (COX) enzymes, thereby reducing prostaglandin synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Win-Max.